Tolfenamic acid is a member of the anthranilic acid derivatives class of NSAID drugs. Like other members of the class, it is a COX inhibitor and prevents formation of prostaglandins. It is used in the UK as a treatment for migraine. It is generally not av + some more technical info. Chemically it is a weakly acidic, lipophilic molecule that exhibits poor aqueous solubility and is typically formulated as oral tablets or capsules; pharmacologically it provides anti-inflammatory, analgesic and antipyretic effects through nonselective inhibition of cyclooxygenase isoenzymes and downstream reduction of prostaglandin synthesis, and it is metabolized primarily by hepatic pathways with renal excretion of metabolites.
Parent: Mefenamic Acid / Mesalazine/ Tolfenamic Acid
Parent: Tolfenamic Acid / Mefenamic Acid
Parent: Tolfenamic Acid
Typical quality control specifications for tolfenamic acid include limits on related substances, degradation products, residual solvents and trace metals; commonly applied acceptance criteria are individual known related impurities controlled at or below 0.1 to 0.3 percent and total related substances controlled at or below 0.5 to 1.0 percent depending on regulatory guidance and daily dose. Common related compounds to monitor are the synthetic precursor 3-chloro-2-methylaniline, positional chloro isomers, the deschloro analogue, N-oxide oxidation product and low-level dimerization products; typical specification examples include 3-chloro-2-methylaniline ≤0.3%, deschloro-tolfenamic acid ≤0.2%, positional isomers ≤0.1% each and N-oxide ≤0.05%, with total impurities not exceeding 0.5 to 1.0% as determined by validated HPLC methods. Residual solvents are controlled to ICH Q3C class limits and heavy metals to pharmacopeial limits, and stability studies define additional degradation thresholds for shelf-life assignment.
Common adverse effects reflect NSAID class properties and include gastrointestinal irritation, dyspepsia, nausea and abdominal pain; less common effects are headache, dizziness and skin reactions. Rare but serious events reported with NSAIDs include gastrointestinal ulceration or bleeding, hepatic enzyme elevations and hypersensitivity reactions. Use with caution in patients with cardiovascular disease, active peptic ulceration or known hypersensitivity to anthranilic acid derivatives.
Tolfenamic acid is used in some veterinary products in certain countries, but safety, dosage and formulation differ from human products. It should only be administered to dogs under veterinary supervision because species-specific sensitivity, dose calculations, drug interactions and contraindications must be assessed by a veterinarian. Do not give human formulations to animals without veterinary guidance.
As with other NSAIDs, tolfenamic acid can impair renal function in susceptible individuals by reducing prostaglandin-mediated renal perfusion, especially in patients who are dehydrated, elderly or taking diuretics, ACE inhibitors or angiotensin receptor blockers. Short-term use in otherwise healthy patients is less likely to cause clinically significant renal injury, but renal function should be monitored in at-risk patients and use avoided or adjusted when renal perfusion is compromised.
“Better” depends on the indication. For inflammatory pain and conditions where prostaglandin-mediated inflammation contributes to symptoms, tolfenamic acid or other NSAIDs are often more effective than paracetamol because of their anti-inflammatory action. Paracetamol has a more favorable gastrointestinal and platelet-sparing safety profile and is preferred when NSAID risks outweigh benefits, but it carries a risk of hepatotoxicity in overdose. Treatment choice should be based on pain mechanism, patient comorbidities and risk assessment.
